CancerDrs

Breast Cancer clinical trials in Texas

93 actively recruiting breast cancer trials at 42 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Texas:
  • Hendrick Medical Center — Abilene, Texas
  • Houston Methodist San Jacinto Hospital — Baytown, Texas
  • MD Anderson in The Woodlands — Conroe, Texas
  • Houston Methodist Cypress Hospital — Cypress, Texas
  • Brooke Army Medical Center — Fort Sam Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Texas:
  • Houston Methodist San Jacinto Hospital — Baytown, Texas
  • UT MD Anderson - The Woodlands — Conroe, Texas
  • Houston Methodist Cypress Hospital — Cypress, Texas
  • Lyndon Baines Johnson General Hospital — Houston, Texas
  • Houston Methodist Hospital — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Texas:
  • Research Site — Dallas, Texas
  • Research Site — Dallas, Texas
  • Research Site — Dallas, Texas
  • Research Site — El Paso, Texas
  • Research Site — Flower Mound, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Texas:
  • Texas Oncology Cancer Center — Austin, Texas
  • JPS Oncology & Infusion Center — Fort Worth, Texas
  • Texas Oncology - DFW — Irving, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced…

Sponsor: AstraZeneca
NCT ID: NCT04862663
Sites in Texas:
  • Research Site — Dallas, Texas
  • Research Site — Fort Worth, Texas
  • Research Site — Houston, Texas
  • Research Site — Irving, Texas
  • Research Site — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Texas:
  • JPS Health Network — Fort Worth, Texas
  • Community Clinical Trials — Kingwood, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Texas:
  • Texas Oncology - Austin — Austin, Texas
  • Texas Oncology - Dallas Presbyterian Hospital — Dallas, Texas
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • The University of Texas Southwestern Medical Center — Dallas, Texas
  • Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Texas:
  • Texas Oncology - Fort Worth — Fort Worth, Texas
  • U.T. MD Anderson Cancer Center, Investigational Pharmacy Services — Houston, Texas
  • Millennium Research and Clinical Development — Houston, Texas
  • Maryland Oncology Hematology Healing Way - USOR — Irving, Texas
  • Medical Oncology Hematology Consultants — Irving, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Texas:
  • Texas Oncology - Central/South Texas — Austin, Texas
  • Texas Oncology - West Texas — El Paso, Texas
  • Texas Oncology - Northeast Texas — Flower Mound, Texas
  • (USOR) Texas Oncology — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Texas:
  • Clinical Trial Site — Denton, Texas
  • Clinical Trial Site — El Paso, Texas
  • Clinical Trial Site — Houston, Texas
  • Clinical Trial Site — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessar…

Sponsor: Uppsala University
NCT ID: NCT04722692
Sites in Texas:
  • Baylor College Of Medicine — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Texas:
  • Hendrick Medical Center — Abilene, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • Lyndon Baines Johnson General Hospital — Houston, Texas
  • Houston Methodist Hospital — Houston, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced…

Sponsor: Pfizer
NCT ID: NCT06966453
Sites in Texas:
  • Texas Oncology-Northeast Texas — Allen, Texas
  • Texas Oncology - DFW — Arlington, Texas
  • Texas Oncology - DFW — Arlington, Texas
  • Texas Oncology - DFW — Bedford, Texas
  • Texas Oncology - DFW — Dallas, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…

Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Texas:
  • University of Texas, Southwestern Medical Center — Dallas, Texas
  • University of Texas, M.D. Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Texas:
  • USOR Texas Oncology — Abilene, Texas
  • Texas Oncology - Central / South Texas — Austin, Texas
  • Mary Crowley Cancer Research — Dallas, Texas
  • USOR Texas Oncology — Fort Worth, Texas
  • Texas Oncology - Northeast TX — Tyler, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Texas:
  • The Methodist Hospital Research Institute — Houston, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Texas:
  • Mary Crowley Cancer Research Center — Dallas, Texas
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • University of Texas Southwestern — Dallas, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • START San Antonio — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Texas:
  • Texas Oncology DFW — Dallas, Texas
  • The University of Texas Southwestern Medical Center — Dallas, Texas
  • Texas Oncology Gulf Coast — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …

Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…

Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Texas:
  • MD Anderson The Woodlands — Conroe, Texas
  • The University of Texas M. D. Anderson Cancer Center — Houston, Texas
  • U.T. MD Anderson Cancer Center — Houston, Texas
  • MD Anderson West Houston — Houston, Texas
  • MD Anderson League City — League City, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…

Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in Texas:
  • University of Texas Southwestern Medical Center — Dallas, Texas
  • Houston Methodist Cancer Center — Houston, Texas
  • The University of Texas M.D. Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven …

Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in Texas:
  • Texas Oncology-Plano East — Plano, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic…

Sponsor: Genentech, Inc.
NCT ID: NCT07100106
Sites in Texas:
  • Texas Oncology (Worth) - USOR — Dallas, Texas
View on ClinicalTrials.gov →

Showing 25 of 93 trials with sites in Texas. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07